Medtronic (NYSE:MDT) Earns Outperform Rating from Royal Bank Of Canada

Medtronic (NYSE:MDT)‘s stock had its “outperform” rating restated by stock analysts at Royal Bank Of Canada in a report issued on Thursday,Benzinga reports. They presently have a $118.00 target price on the medical technology company’s stock. Royal Bank Of Canada’s price target points to a potential upside of 45.52% from the stock’s previous close.

Several other research analysts have also recently commented on MDT. Stifel Nicolaus set a $80.00 target price on shares of Medtronic in a report on Wednesday. Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a report on Saturday, April 11th. BTIG Research set a $90.00 price objective on Medtronic in a research report on Wednesday. Leerink Partners lowered their price objective on Medtronic from $117.00 to $104.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, Robert W. Baird cut their price target on Medtronic from $93.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday. Sixteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $100.86.

Medtronic Trading Up 4.0%

NYSE:MDT opened at $81.09 on Thursday. The company has a market cap of $104.11 billion, a PE ratio of 22.49, a P/E/G ratio of 1.76 and a beta of 0.58. The business’s 50 day moving average is $81.67 and its two-hundred day moving average is $92.21. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. Medtronic has a 52 week low of $73.31 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. The business had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, analysts predict that Medtronic will post 5.54 EPS for the current year.

Hedge Funds Weigh In On Medtronic

Several hedge funds and other institutional investors have recently modified their holdings of the business. Norges Bank bought a new stake in shares of Medtronic during the fourth quarter worth about $1,653,485,000. WCM Investment Management LLC purchased a new stake in shares of Medtronic in the first quarter worth approximately $965,922,000. Capital Research Global Investors lifted its holdings in shares of Medtronic by 12.6% in the fourth quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock valued at $3,321,101,000 after purchasing an additional 3,880,174 shares in the last quarter. Barclays PLC boosted its position in shares of Medtronic by 104.6% during the third quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock valued at $650,604,000 after buying an additional 3,492,192 shares during the last quarter. Finally, Schroder Investment Management Group grew its holdings in Medtronic by 78.3% during the third quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company’s stock worth $717,143,000 after buying an additional 3,307,211 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported fiscal Q4 revenue of $9.81 billion and adjusted EPS of $1.55, both ahead of estimates, which reinforced the recent stock move higher.
• Positive Sentiment: Cardiac Ablation Solutions revenue surged 78% globally, helping offset margin pressure and signaling strong demand in a key growth franchise.
• Positive Sentiment: Management lifted its quarterly dividend to $0.72 per share and kept FY2027 growth targets intact, supporting the case for continued operational momentum.
• Positive Sentiment: Medtronic also announced new strategic investments and FDA-related submissions to expand its Hugo robotic-assisted surgery platform, which could add future growth opportunities. Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery system
• Neutral Sentiment: Several analysts lowered price targets this morning, but most kept constructive ratings such as overweight, outperform, or buy, suggesting valuation concerns rather than a changed bullish thesis.
• Neutral Sentiment: Wells Fargo cut its target to $102 from $114 and Leerink cut to $104 from $117, while Robert W. Baird reduced its target to $85 and kept a neutral rating.
• Negative Sentiment: Medtronic’s FY2027 EPS guidance of $5.90 to $6.00 came in below the consensus estimate, which may temper some of the post-earnings enthusiasm.
• Negative Sentiment: Margins remain a focus as the company flagged tariff and cost headwinds, which could pressure profitability even as sales improve.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).